```html

Labial (Vulvar) Cancer – Comprehensive Medical Guide

Overview

Labial (vulvar) cancer is a malignant tumor that originates in the tissues of the vulva, the external part of the female genitalia that includes the labia majora, labia minora, clitoral hood, and the opening of the vagina. The most common histologic type is squamous cell carcinoma (SCC), accounting for about 85‑90 % of cases, but other types such as melanoma, adenocarcinoma, and basal cell carcinoma can also arise.

Although vulvar cancer is relatively rare compared with cervical or breast cancer, it represents an important health issue because it often presents at a later stage and can significantly affect quality of life.

• Incidence in the United States: ≈ 6‑7 per 100,000 women per year (≈ 4,000 new cases annually) (CDC).
• Global burden: ≈ 45,000 new cases and 17,000 deaths per year (IARC).
• Median age at diagnosis: 65 years; however, a rising incidence is observed in women under 50 who have human papillomavirus (HPV) infection.

The disease can affect any woman, but risk increases with age, persistent HPV infection, smoking, immunosuppression, and a history of precancerous vulvar lesions (VIN – vulvar intraepithelial neoplasia).

Symptoms

Symptoms are often subtle early on, which contributes to delayed diagnosis. Women should be familiar with the following warning signs:

• Persistent itching or burning of the vulva or labia that does not improve with typical topical treatments.
• Lumps or thickened areas on the labia, clitoral hood, or around the vaginal opening.
• Ulcerated or non‑healing sores that may bleed or discharge.
• Changes in skin color or texture, such as redness, white patches (leukoplakia), or a velvety appearance.
• Painful sexual intercourse (dyspareunia) or pain on sitting.
• Unexplained vaginal bleeding or spotting, especially after menopause.
• Swelling or a feeling of fullness in the groin area, which may indicate lymph node involvement.
• Foul odor or persistent discharge from the vulva.
• General symptoms such as unexplained weight loss, fatigue, or night sweats may appear in advanced disease.

Any new, persistent, or worsening vulvar symptom lasting > 4 weeks should prompt a medical evaluation.

Causes and Risk Factors

Labial cancer is multifactorial. The following are the most recognized contributors:

Human Papillomavirus (HPV)

High‑risk HPV types (especially 16 and 18) are implicated in up to 40 % of vulvar SCCs, particularly in younger women. The virus promotes cellular dysplasia that can progress to cancer if untreated.

Age

Incidence rises sharply after age 55, likely reflecting cumulative DNA damage and declining immune surveillance.

Smoking

Cigarette smoking is an independent risk factor; tobacco carcinogens may act synergistically with HPV, and smoking impairs local immune responses.

Chronic Vulvar Dermatoses

Lichen sclerosus, a chronic inflammatory skin condition, is strongly linked to “non‑HPV‑related” vulvar SCC, often occurring in older women.

Immunosuppression

Women with HIV, organ transplantation, or long‑term corticosteroid use have higher rates of vulvar neoplasia.

Previous Cancer or Precancerous Lesions

A history of VIN, cervical cancer, or anal cancer increases risk, reflecting a field‑cancer effect of HPV.

Other Factors

• Genetic predisposition (e.g., BRCA mutations, though data are limited).
• Exposure to industrial chemicals or radiation (rare).

Diagnosis

Early diagnosis hinges on a thorough clinical assessment followed by targeted diagnostic tests.

Clinical Examination

• Visual inspection of the vulva in a well‑lit environment.
• Palpation of the labia, clitoris, and inguinal lymph nodes.
• Speculum exam to evaluate the vaginal introitus.

Biopsy

A punch, excisional, or incisional biopsy of any suspicious lesion is essential. Pathology determines tumor type, grade, and presence of HPV DNA (via PCR or in‑situ hybridization).

Imaging Studies

• Pelvic MRI: Best for assessing depth of invasion and surrounding soft tissue.
• CT scan of abdomen/pelvis: Evaluates distant spread and lymph node size.
• PET‑CT: Detects metabolically active metastatic disease, useful for staging.

Staging

The FIGO (International Federation of Gynecology and Obstetrics) 2023 staging system is used, ranging from Stage 0 (carcinoma in situ) to Stage IV (advanced metastatic disease). Staging guides treatment planning.

Laboratory Tests

• Complete blood count, liver and renal function tests (baseline before treatment).
• HPV typing (optional, helps in counseling and follow‑up).

Treatment Options

Treatment is individualized based on stage, tumor size, location, patient age, comorbidities, and preferences. Multidisciplinary care (gynecologic oncology, radiation oncology, pathology, nursing, and psycho‑social support) is the standard.

Surgery

• Local excision (wide local excision) for early, small (< 2 cm) lesions with clear margins.
• Radical vulvectomy (removal of the entire vulva) for larger tumors or when margins are uncertain.
• Inguinal‑femoral lymphadenectomy (removal of lymph nodes) when clinical nodal disease is present.
• Sentinel lymph node mapping (using dye or radiocolloid) can spare many women from full‑node dissection and reduce lymphedema risk.

Radiation Therapy

• External beam radiation therapy (EBRT) as primary treatment for patients who are not surgical candidates.
• Adjuvant radiation (often combined with chemotherapy) after surgery when margins are close or nodes are positive.

Chemotherapy

Platinum‑based regimens (cisplatin or carboplatin) combined with 5‑fluorouracil (5‑FU) are common, especially when radiation is given (chemoradiation). For metastatic disease, regimens may include taxanes, pembrolizumab (PD‑1 inhibitor) for PD‑L1‑positive tumors, or checkpoint inhibitors per NCCN guidelines.

Targeted & Immunotherapy

• Pembrolizumab is FDA‑approved for PD‑L1‑positive recurrent/metastatic vulvar SCC.
• Clinical trials are evaluating EGFR inhibitors and therapeutic HPV vaccines.

Supportive & Lifestyle Measures

• Smoking cessation (improves wound healing and reduces recurrence).
• Nutrition counseling to maintain adequate protein and calorie intake during treatment.
• Pain management (NSAIDs, neuropathic agents, or opioids as needed).
• Lymphedema prevention: compression garments, physiotherapy.

Living with Labial (Vulvar) Cancer

After diagnosis and treatment, ongoing self‑care and follow‑up are crucial.

Physical Care

• Perineal hygiene: Gentle cleansing with water; avoid scented soaps and tight clothing.
• Wound care: Keep surgical sites clean, follow provider instructions for dressings, and report signs of infection.
• Pelvic floor exercises (Kegels) to improve muscle tone, especially after extensive surgery.
• Lymphedema monitoring: Daily inspection of groin/leg swelling; use compression stockings if prescribed.

Emotional & Psychosocial Support

• Join support groups (e.g., Gyn-Onc Support Network, CancerCare).
• Consider counseling or sex therapy to address body‑image changes and sexual dysfunction.
• Communicate openly with partners about intimacy concerns.

Follow‑up Schedule

Typical NCCN recommendations:

• Every 3–4 months during the first 2 years (history, physical, pelvic exam, and inguinal node check).
• Every 6 months for years 3‑5.
• Annually thereafter.

Imaging is performed based on symptoms or if there is concern for recurrence.

Fertility & Sexual Health

Though many patients are post‑menopausal, younger women may face fertility concerns. Discuss sperm/egg preservation before treatment. Use water‑based lubricants and pelvic‑floor therapy to reduce dyspareunia.

Prevention

Because many risk factors are modifiable, prevention efforts can lower incidence.

• HPV vaccination: The 9‑valent vaccine (Gardasil 9) protects against HPV 16/18 and other oncogenic types. CDC recommends routine vaccination at ages 11‑12 for all genders, with catch‑up through age 26 (and shared‑decision making up to age 45).
• Smoking cessation: Quit programs, nicotine replacement therapy, or medications such as varenicline.
• Safe sexual practices: Condom use and limiting number of sexual partners reduce HPV exposure.
• Management of chronic vulvar dermatoses: Treat lichen sclerosus with high‑potency topical steroids (e.g., clobetasol) and regular follow‑up.
• Regular gynecologic exams: Early detection of VIN or suspicious lesions enables timely excision before progression.

Complications

If left untreated or in advanced stages, vulvar cancer can cause:

• Local tissue invasion → ulceration, fistula formation, and severe pain.
• Inguinal lymph node metastasis → lymphedema, cellulitis, or deep‑vein thrombosis.
• Pelvic or distant metastasis (lungs, liver, bone) → organ dysfunction.
• Psychological impact: depression, anxiety, and sexual dysfunction.
• Treatment‑related complications: wound breakdown, urinary retention, sexual dysfunction, and chronic pain.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Cancer Institute, WHO, Cleveland Clinic, NCCN Clinical Practice Guidelines in Oncology (vulvar cancer), International Agency for Research on Cancer (IARC).

```